Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 65865-65867 [E8-26466]
Download as PDF
Federal Register / Vol. 73, No. 215 / Wednesday, November 5, 2008 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
hsrobinson on PROD1PC76 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Organ
Transplantation Program Projects.
Date: December 3, 2008.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Carol J. Goter-Robinson,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 748, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7791,
goterrobinsonc@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, HIV-Associated
Nephropathy.
Date: December 11, 2008.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call)
Contact Person: Lakshmanan Sankaran,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 755, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7799, ls38z@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
VerDate Aug<31>2005
17:24 Nov 04, 2008
Jkt 217001
Dated: October 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–26339 Filed 11–4–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
65865
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
ACL Laboratories
8901 W. Lincoln Ave.
West Allis, WI 53227
414–328–7840/800–877–7016
(Formerly: Bayshore Clinical
Laboratory)
ACM Medical Laboratory, Inc.
160 Elmgrove Park
Rochester, NY 14624
585–429–2264
Advanced Toxicology Network
3560 Air Center Cove, Suite 101
Memphis, TN 38118
901–794–5770/888–290–1150
Aegis Sciences Corporation
345 Hill Ave.
Nashville, TN 37210
615–255–2400
(Formerly: Aegis Analytical
Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory
9601 I–630, Exit 7
Little Rock, AR 72205–7299
501–202–2783
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab
8433 Quivira Road
Lenexa, KS 66215–2802
800–445–6917
Diagnostic Services, Inc., dba DSI
12700 Westlinks Drive
Fort Myers, FL 33913
239–561–8200/800–735–5416
Doctors Laboratory, Inc.
2906 Julia Drive
Valdosta, GA 31602
229–671–2281
DrugScan, Inc.
E:\FR\FM\05NON1.SGM
05NON1
hsrobinson on PROD1PC76 with NOTICES
65866
Federal Register / Vol. 73, No. 215 / Wednesday, November 5, 2008 / Notices
P.O. Box 2969
1119 Mearns Road
Warminster, PA 18974
215–674–9310
DynaLIFE Dx *
10150–102 St., Suite 200
Edmonton, Alberta
Canada T5J 5E2
780–451–3702/800–661–9876
(Formerly: Dynacare Kasper Medical
Laboratories)
ElSohly Laboratories, Inc.
5 Industrial Park Drive
Oxford, MS 38655
662–236–2609
Gamma-Dynacare Medical Laboratories*
A Division of the Gamma-Dynacare
Laboratory Partnership
245 Pall Mall Street
London, ONT, Canada N6A 1P4
519–679–1630
Kroll Laboratory Specialists, Inc.
1111 Newton St.
Gretna, LA 70053
504–361–8989/800–433–3823
(Formerly: Laboratory Specialists, Inc.)
Kroll Laboratory Specialists, Inc.
450 Southlake Blvd.
Richmond, VA 23236
804–378–9130
(Formerly: Scientific Testing
Laboratories, Inc.; Kroll Scientific
Testing Laboratories, Inc.)
Laboratory Corporation of America
Holdings
7207 N. Gessner Road
Houston, TX 77040
713–856–8288/800–800–2387
Laboratory Corporation of America
Holdings
69 First Ave.
Raritan, NJ 08869
908–526–2400/800–437–4986
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings
1904 Alexander Drive
Research Triangle Park, NC 27709
919–572–6900/800–833–3984
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings
1120 Main Street
Southaven, MS 38671
866–827–8042/800–233–6339
(Formerly: LabCorp Occupational
Testing Services, Inc.; MedExpress/
National Laboratory Center)
LabOne, Inc. d/b/a Quest Diagnostics
10101 Renner Blvd.
VerDate Aug<31>2005
17:24 Nov 04, 2008
Jkt 217001
Lenexa, KS 66219
913–888–3927/800–873–8845
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Maxxam Analytics*
6740 Campobello Road
Mississauga, ON
Canada L5N 2L8
905–817–5700
(Formerly: Maxxam Analytics Inc.,
NOVAMANN (Ontario), Inc.)
MedTox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services
1225 NE 2nd Ave.
Portland, OR 97232
503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center
Forensic Toxicology Laboratory
1 Veterans Drive
Minneapolis, MN 55417
612–725–2088
National Toxicology Laboratories, Inc.
1100 California Ave.
Bakersfield, CA 93304
661–322–4250/800–350–3515
One Source Toxicology Laboratory, Inc.
1213 Genoa-Red Bluff
Pasadena, TX 77504
888–747–3774
(Formerly: University of Texas Medical
Branch, Clinical Chemistry Division;
UTMB Pathology-Toxicology
Laboratory)
Oregon Medical Laboratories
123 International Way
Springfield, OR 97477
541–341–8092
Pacific Toxicology Laboratories
9348 DeSoto Ave.
Chatsworth, CA 91311
800–328–6942
(Formerly: Centinela Hospital Airport
Toxicology Laboratory)
Pathology Associates Medical
Laboratories
110 West Cliff Dr.
Spokane, WA 99204
509–755–8991 / 800–541–7891x7
Pharmatech, Inc.
10151 Barnes Canyon Road
San Diego, CA 92121
858–643–5555
Quest Diagnostics Incorporated
3175 Presidential Dr.
Atlanta, GA 30340
770–452–1590 / 800–729–6432
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
400 Egypt Road
Norristown, PA 19403
610–631–4600 / 877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated
7600 Tyrone Ave.
Van Nuys, CA 91405
866–370–6699 / 818–989–2521
(Formerly: SmithKline Beecham
Clinical Laboratories)
S.E.D. Medical Laboratories
5601 Office Blvd.
Albuquerque, NM 87109
505–727–6300 / 800–999–5227
South Bend Medical Foundation, Inc.
530 N. Lafayette Blvd.
South Bend, IN 46601
574–234–4176 x276
Southwest Laboratories
4645 E. Cotton Center Boulevard
Suite 177
Phoenix, AZ 85040
602–438–8507 / 800–279–0027
Sparrow Health System
Toxicology Testing Center, St. Lawrence
Campus
1210 W. Saginaw
Lansing, MI 48915
517–364–7400
(Formerly: St. Lawrence Hospital &
Healthcare System)
St. Anthony Hospital Toxicology
Laboratory
1000 N. Lee St.
Oklahoma City, OK 73101
405–272–7052
Toxicology & Drug Monitoring
Laboratory
University of Missouri Hospital &
Clinics
301 Business Loop 70 West, Suite 208
Columbia, MO 65203
573–882–1273
Toxicology Testing Service, Inc.
5426 N.W. 79th Ave.
Miami, FL 33166
305–593–2260
US Army Forensic Toxicology Drug
Testing Laboratory
2490 Wilson St.
Fort George G. Meade, MD 20755–5235
301–677–7085
The following laboratory will be
voluntarily withdrawing from the
National Laboratory Certification
Program on November 15, 2008:
Laboratory Corporation of America
Holdings
550 17th Ave., Suite 300
Seattle, WA 98122
206–923–7020 / 800–898–0180
(Formerly: DrugProof, Division of
Dynacare/Laboratory of Pathology,
LLC; Laboratory of Pathology of
Seattle, Inc.; DrugProof, Division of
E:\FR\FM\05NON1.SGM
05NON1
Federal Register / Vol. 73, No. 215 / Wednesday, November 5, 2008 / Notices
Laboratory of Pathology of Seattle,
Inc.)
*The Standards Council of Canada (SCC)
voted to end its Laboratory Accreditation
Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified
through that program were accredited to
conduct forensic urine drug testing as
required by U.S. Department of
Transportation (DOT) regulations. As of that
date, the certification of those accredited
Canadian laboratories will continue under
DOT authority. The responsibility for
conducting quarterly performance testing
plus periodic on-site inspections of those
LAPSA-accredited laboratories was
transferred to the U.S. HHS, with the HHS’
NLCP contractor continuing to have an active
role in the performance testing and
laboratory inspection processes. Other
Canadian laboratories wishing to be
considered for the NLCP may apply directly
to the NLCP contractor just as U.S.
laboratories do.
Upon finding a Canadian laboratory to be
qualified, HHS will recommend that DOT
certify the laboratory (Federal Register, July
16, 1996) as meeting the minimum standards
of the Mandatory Guidelines published in the
Federal Register on April 13, 2004 (69 FR
19644). After receiving DOT certification, the
laboratory will be included in the monthly
list of HHS-certified laboratories and
participate in the NLCP certification
maintenance program.
Elaine Parry,
Acting Director, Office of Program Services,
SAMHSA.
[FR Doc. E8–26466 Filed 11–4–08; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HOMELAND
SECURITY
a major disaster under the authority of
the Robert T. Stafford Disaster Relief
and Emergency Assistance Act, 42
U.S.C. 5121–5207 (the Stafford Act), as
follows:
I have determined that the damage in
certain areas of the State of Florida resulting
from Hurricane Gustav during the period of
August 31 to September 7, 2008, is of
sufficient severity and magnitude to warrant
a major disaster declaration under the Robert
T. Stafford Disaster Relief and Emergency
Assistance Act, 42 U.S.C. 5121–5207 (the
Stafford Act). Therefore, I declare that such
a major disaster exists in the State of Florida.
In order to provide Federal assistance, you
are hereby authorized to allocate from funds
available for these purposes such amounts as
you find necessary for Federal disaster
assistance and administrative expenses.
You are authorized to provide Public
Assistance in the designated areas, Hazard
Mitigation throughout the State, and any
other forms of assistance under the Stafford
Act that you deem appropriate. Consistent
with the requirement that Federal assistance
be supplemental, any Federal funds provided
under the Stafford Act for Hazard Mitigation
will be limited to 75 percent of the total
eligible costs. Federal funds provided under
the Stafford Act for Public Assistance also
will be limited to 75 percent of the total
eligible costs, except for any particular
projects that are eligible for a higher Federal
cost-sharing percentage under the FEMA
Public Assistance Pilot Program instituted
pursuant to 6 U.S.C. 777. If Other Needs
Assistance under Section 408 of the Stafford
Act is later requested and warranted, Federal
funding under that program also will be
limited to 75 percent of the total eligible
costs.
Further, you are authorized to make
changes to this declaration to the extent
allowable under the Stafford Act.
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
The Federal Emergency Management
Agency (FEMA) hereby gives notice that
pursuant to the authority vested in the
Administrator, under Executive Order
12148, as amended, Jeffery L. Bryant, of
FEMA is appointed to act as the Federal
Coordinating Officer for this declared
disaster.
The following areas of the State of
Florida have been designated as
adversely affected by this declared
major disaster:
SUMMARY: This is a notice of the
Presidential declaration of a major
disaster for the State of Florida (FEMA–
1806–DR), dated October 27, 2008, and
related determinations.
DATES: Effective Date: October 27, 2008.
FOR FURTHER INFORMATION CONTACT:
Peggy Miller, Disaster Assistance
Directorate, Federal Emergency
Management Agency, 500 C Street, SW.,
Washington, DC 20472, (202) 646–3886.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that, in a letter dated
October 27, 2008, the President declared
Bay, Escambia, Franklin, Gulf, Okaloosa,
and Santa Rosa Counties for Public
Assistance.
All counties within the State of Florida are
eligible to apply for assistance under the
Hazard Mitigation Grant Program.
The following Catalog of Federal Domestic
Assistance Numbers (CFDA) are to be used
for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora
Brown Fund; 97.032, Crisis Counseling;
97.033, Disaster Legal Services; 97.034,
Disaster Unemployment Assistance (DUA);
97.046, Fire Management Assistance Grant;
97.048, Disaster Housing Assistance to
Individuals and Households In Presidentially
Federal Emergency Management
Agency
[FEMA–1806–DR]
Florida; Major Disaster and Related
Determinations
hsrobinson on PROD1PC76 with NOTICES
AGENCY:
VerDate Aug<31>2005
17:24 Nov 04, 2008
Jkt 217001
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
65867
Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance—
Disaster Housing Operations for Individuals
and Households; 97.050, Presidentially
Declared Disaster Assistance to Individuals
and Households—Other Needs; 97.036,
Disaster Grants—Public Assistance
(Presidentially Declared Disasters); 97.039,
Hazard Mitigation Grant.
R. David Paulison,
Administrator, Federal Emergency
Management Agency.
[FR Doc. E8–26298 Filed 11–4–08; 8:45 am]
BILLING CODE 9111–23–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[FEMA–1805–DR]
Ohio; Major Disaster and Related
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is a notice of the
Presidential declaration of a major
disaster for the State of Ohio (FEMA–
1805–DR), dated October 24, 2008, and
related determinations.
DATES: Effective Date: October 24, 2008.
FOR FURTHER INFORMATION CONTACT:
Peggy Miller, Disaster Assistance
Directorate, Federal Emergency
Management Agency, 500 C Street, SW.,
Washington, DC 20472, (202) 646–3886.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that, in a letter dated
October 24, 2008, the President declared
a major disaster under the authority of
the Robert T. Stafford Disaster Relief
and Emergency Assistance Act, 42
U.S.C. 5121–5207 (the Stafford Act), as
follows:
I have determined that the damage in
certain areas of the State of Ohio resulting
from a severe wind storm associated with
Tropical Depression Ike on September 14,
2008, is of sufficient severity and magnitude
to warrant a major disaster declaration under
the Robert T. Stafford Disaster Relief and
Emergency Assistance Act, 42 U.S.C. 5121–
5207 (the Stafford Act). Therefore, I declare
that such a major disaster exists in the State
of Ohio.
In order to provide Federal assistance, you
are hereby authorized to allocate from funds
available for these purposes such amounts as
you find necessary for Federal disaster
assistance and administrative expenses.
You are authorized to provide Public
Assistance in the designated areas, Hazard
Mitigation throughout the State, and any
other forms of assistance under the Stafford
Act that you deem appropriate. Consistent
E:\FR\FM\05NON1.SGM
05NON1
Agencies
[Federal Register Volume 73, Number 215 (Wednesday, November 5, 2008)]
[Notices]
[Pages 65865-65867]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26466]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories Which Meet Minimum Standards To
Engage in Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories currently certified to meet the
standards of Subpart C of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory
Guidelines were first published in the Federal Register on April 11,
1988 (53 FR 11970), and subsequently revised in the Federal Register on
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on
April 13, 2004 (69 FR 19644).
A notice listing all currently certified laboratories is published
in the Federal Register during the first week of each month. If any
laboratory's certification is suspended or revoked, the laboratory will
be omitted from subsequent lists until such time as it is restored to
full certification under the Mandatory Guidelines.
If any laboratory has withdrawn from the HHS National Laboratory
Certification Program (NLCP) during the past month, it will be listed
at the end, and will be omitted from the monthly listing thereafter.
This notice is also available on the Internet at https://
www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in
accordance with Executive Order 12564 and section 503 of Public Law
100-71. Subpart C of the Mandatory Guidelines, ``Certification of
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets
strict standards that laboratories must meet in order to conduct drug
and specimen validity tests on urine specimens for Federal agencies. To
become certified, an applicant laboratory must undergo three rounds of
performance testing plus an on-site inspection. To maintain that
certification, a laboratory must participate in a quarterly performance
testing program plus undergo periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of
certification are not to be considered as meeting the minimum
requirements described in the HHS Mandatory Guidelines. A laboratory
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
In accordance with Subpart C of the Mandatory Guidelines dated
April 13, 2004 (69 FR 19644), the following laboratories meet the
minimum standards to conduct drug and specimen validity tests on urine
specimens:
ACL Laboratories
8901 W. Lincoln Ave.
West Allis, WI 53227
414-328-7840/800-877-7016
(Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc.
160 Elmgrove Park
Rochester, NY 14624
585-429-2264
Advanced Toxicology Network
3560 Air Center Cove, Suite 101
Memphis, TN 38118
901-794-5770/888-290-1150
Aegis Sciences Corporation
345 Hill Ave.
Nashville, TN 37210
615-255-2400
(Formerly: Aegis Analytical Laboratories, Inc.)
Baptist Medical Center-Toxicology Laboratory
9601 I-630, Exit 7
Little Rock, AR 72205-7299
501-202-2783
(Formerly: Forensic Toxicology Laboratory Baptist Medical Center)
Clinical Reference Lab
8433 Quivira Road
Lenexa, KS 66215-2802
800-445-6917
Diagnostic Services, Inc., dba DSI
12700 Westlinks Drive
Fort Myers, FL 33913
239-561-8200/800-735-5416
Doctors Laboratory, Inc.
2906 Julia Drive
Valdosta, GA 31602
229-671-2281
DrugScan, Inc.
[[Page 65866]]
P.O. Box 2969
1119 Mearns Road
Warminster, PA 18974
215-674-9310
DynaLIFE Dx *
10150-102 St., Suite 200
Edmonton, Alberta
Canada T5J 5E2
780-451-3702/800-661-9876
(Formerly: Dynacare Kasper Medical Laboratories)
ElSohly Laboratories, Inc.
5 Industrial Park Drive
Oxford, MS 38655
662-236-2609
Gamma-Dynacare Medical Laboratories*
A Division of the Gamma-Dynacare Laboratory Partnership
245 Pall Mall Street
London, ONT, Canada N6A 1P4
519-679-1630
Kroll Laboratory Specialists, Inc.
1111 Newton St.
Gretna, LA 70053
504-361-8989/800-433-3823
(Formerly: Laboratory Specialists, Inc.)
Kroll Laboratory Specialists, Inc.
450 Southlake Blvd.
Richmond, VA 23236
804-378-9130
(Formerly: Scientific Testing Laboratories, Inc.; Kroll Scientific
Testing Laboratories, Inc.)
Laboratory Corporation of America Holdings
7207 N. Gessner Road
Houston, TX 77040
713-856-8288/800-800-2387
Laboratory Corporation of America Holdings
69 First Ave.
Raritan, NJ 08869
908-526-2400/800-437-4986
(Formerly: Roche Biomedical Laboratories, Inc.)
Laboratory Corporation of America Holdings
1904 Alexander Drive
Research Triangle Park, NC 27709
919-572-6900/800-833-3984
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche
Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of
the Roche Group)
Laboratory Corporation of America Holdings
1120 Main Street
Southaven, MS 38671
866-827-8042/800-233-6339
(Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/
National Laboratory Center)
LabOne, Inc. d/b/a Quest Diagnostics
10101 Renner Blvd.
Lenexa, KS 66219
913-888-3927/800-873-8845
(Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of LabOne, Inc.)
Maxxam Analytics*
6740 Campobello Road
Mississauga, ON
Canada L5N 2L8
905-817-5700
(Formerly: Maxxam Analytics Inc., NOVAMANN (Ontario), Inc.)
MedTox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
651-636-7466/800-832-3244
MetroLab-Legacy Laboratory Services
1225 NE 2nd Ave.
Portland, OR 97232
503-413-5295/800-950-5295
Minneapolis Veterans Affairs Medical Center
Forensic Toxicology Laboratory
1 Veterans Drive
Minneapolis, MN 55417
612-725-2088
National Toxicology Laboratories, Inc.
1100 California Ave.
Bakersfield, CA 93304
661-322-4250/800-350-3515
One Source Toxicology Laboratory, Inc.
1213 Genoa-Red Bluff
Pasadena, TX 77504
888-747-3774
(Formerly: University of Texas Medical Branch, Clinical Chemistry
Division; UTMB Pathology-Toxicology Laboratory)
Oregon Medical Laboratories
123 International Way
Springfield, OR 97477
541-341-8092
Pacific Toxicology Laboratories
9348 DeSoto Ave.
Chatsworth, CA 91311
800-328-6942
(Formerly: Centinela Hospital Airport Toxicology Laboratory)
Pathology Associates Medical Laboratories
110 West Cliff Dr.
Spokane, WA 99204
509-755-8991 / 800-541-7891x7
Pharmatech, Inc.
10151 Barnes Canyon Road
San Diego, CA 92121
858-643-5555
Quest Diagnostics Incorporated
3175 Presidential Dr.
Atlanta, GA 30340
770-452-1590 / 800-729-6432
(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-
Science Laboratories)
Quest Diagnostics Incorporated
400 Egypt Road
Norristown, PA 19403
610-631-4600 / 877-642-2216
(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-
Science Laboratories)
Quest Diagnostics Incorporated
7600 Tyrone Ave.
Van Nuys, CA 91405
866-370-6699 / 818-989-2521
(Formerly: SmithKline Beecham Clinical Laboratories)
S.E.D. Medical Laboratories
5601 Office Blvd.
Albuquerque, NM 87109
505-727-6300 / 800-999-5227
South Bend Medical Foundation, Inc.
530 N. Lafayette Blvd.
South Bend, IN 46601
574-234-4176 x276
Southwest Laboratories
4645 E. Cotton Center Boulevard
Suite 177
Phoenix, AZ 85040
602-438-8507 / 800-279-0027
Sparrow Health System
Toxicology Testing Center, St. Lawrence Campus
1210 W. Saginaw
Lansing, MI 48915
517-364-7400
(Formerly: St. Lawrence Hospital & Healthcare System)
St. Anthony Hospital Toxicology Laboratory
1000 N. Lee St.
Oklahoma City, OK 73101
405-272-7052
Toxicology & Drug Monitoring Laboratory
University of Missouri Hospital & Clinics
301 Business Loop 70 West, Suite 208
Columbia, MO 65203
573-882-1273
Toxicology Testing Service, Inc.
5426 N.W. 79th Ave.
Miami, FL 33166
305-593-2260
US Army Forensic Toxicology Drug Testing Laboratory
2490 Wilson St.
Fort George G. Meade, MD 20755-5235
301-677-7085
The following laboratory will be voluntarily withdrawing from the
National Laboratory Certification Program on November 15, 2008:
Laboratory Corporation of America Holdings
550 17th Ave., Suite 300
Seattle, WA 98122
206-923-7020 / 800-898-0180
(Formerly: DrugProof, Division of Dynacare/Laboratory of Pathology,
LLC; Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of
[[Page 65867]]
Laboratory of Pathology of Seattle, Inc.)
*The Standards Council of Canada (SCC) voted to end its
Laboratory Accreditation Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified through that program
were accredited to conduct forensic urine drug testing as required
by U.S. Department of Transportation (DOT) regulations. As of that
date, the certification of those accredited Canadian laboratories
will continue under DOT authority. The responsibility for conducting
quarterly performance testing plus periodic on-site inspections of
those LAPSA-accredited laboratories was transferred to the U.S. HHS,
with the HHS' NLCP contractor continuing to have an active role in
the performance testing and laboratory inspection processes. Other
Canadian laboratories wishing to be considered for the NLCP may
apply directly to the NLCP contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July
16, 1996) as meeting the minimum standards of the Mandatory
Guidelines published in the Federal Register on April 13, 2004 (69
FR 19644). After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program.
Elaine Parry,
Acting Director, Office of Program Services, SAMHSA.
[FR Doc. E8-26466 Filed 11-4-08; 8:45 am]
BILLING CODE 4160-20-P